Apimeds Pharmaceuticals US APUS
NYSE APUS
$3.25 -0.25 (-7.14%)
As of: Oct 20, 2026 · 3:58 PM EDT

Apimeds Pharmaceuticals US (APUS) EBIT (2024 - 2026)

Updated

Apimeds Pharmaceuticals US (APUS) reported EBIT of -$6.28 million for Q2 2026, compared with -$2.66 million a year earlier.

Analysis

Apimeds Pharmaceuticals US (APUS) EBIT (2024 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Apimeds Pharmaceuticals US's EBIT came in at -$17.83 million; for FY2025, it came in at -$11.91 million.

  • By year, EBIT came in at -$1.28 million in FY2024 and -$747,436 in FY2023.
  • Five-year quarterly EBIT spans a low of -$7.04 million in Q4 2025 and a high of -$271,726 in Q1 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT (Qtr)
1 Eli Lilly 1,146.94 Bn 1,115.53 Bn 19.71 Bn 11.75 Bn
2 Johnson & Johnson 624.96 Bn 543.49 Bn 17.26 Bn 7.14 Bn
3 AbbVie 510.15 Bn 483.27 Bn 12.70 Bn 6.43 Bn
4 Merck 366.13 Bn 320.51 Bn 12.21 Bn -584.00 Mn
5 Novartis Ag 297.75 Bn 261.74 Bn 11.24 Bn 4.75 Bn
6 Astrazeneca 261.93 Bn 235.62 Bn 12.86 Bn 3.16 Bn
7 Amgen 236.51 Bn 191.91 Bn 7.24 Bn 3.51 Bn
8 Gilead Sciences 194.27 Bn 168.47 Bn 6.22 Bn -10.39 Bn
9 Pfizer 171.74 Bn 118.39 Bn 10.94 Bn 4.27 Bn
10 Apimeds Pharmaceuticals US 5.65 Mn -13.98 Mn - -6.28 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -6.28 Mn
Dec 31, 2025 -7.04 Mn
Sep 30, 2025 -1.84 Mn
Jun 30, 2025 -2.66 Mn
Mar 31, 2025 -364,368.00
Dec 31, 2024 -275,613.00
Sep 30, 2024 -299,999.00
Jun 30, 2024 -427,757.00
Mar 31, 2024 -271,726.00
API Access

Apimeds Pharmaceuticals US EBIT API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit&ticker=APUS&period=max&api_key=YOUR_API_KEY